ADPT Insider Sharon Benzeno Buys $752K of Stock
Sharon Benzeno, Chief Commercial Officer, bought over 103,000 shares of Adaptive Biotechnologies, valued at about $751,605, on June 29, 2026.
Reviewed by automated data checks against the source filing. How we make and check alerts
Sharon Benzeno, Chief Commercial Ofc Imm Med at Adaptive Biotechnologies Corporation ($ADPT), bought 103,295 shares at an average price of $7.28, worth about $751,605.41, on June 29, 2026. The trade was reported to the SEC in a Form 4 filing.
Since the trade, $ADPT is up 0.5% after 1 week, up 5.4% after 1 month and up 12.2% to date (from the $21.40 close on Jun 29, 2026).
ADPT
Adaptive Biotechnologies Corporation
Key Points
- Sharon Benzeno purchased 103,295 shares of Adaptive Biotechnologies for $751,605 on June 29, 2026, while the stock was trading at $22.16.
- The company reported revenue of $308.1 million for the last year, showing a growth rate of 21.5%, but is currently unprofitable.
- Analysts maintain a strong buy rating for the stock, with a consensus price target of $26.36, reflecting optimism about its future performance.
Get $ADPT trade alerts by text
We text you when insiders, Congress or big funds trade $ADPT. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Adaptive Biotechnologies Corporation alert may contain errors. Disclosures
Insider Buying and Selling at Adaptive Biotechnologies Corporation
Sharon Benzeno, the Chief Commercial Officer of Adaptive Biotechnologies Corporation (ADPT) on the NasdaqGS, bought 103,295 shares on June 29, 2026. This purchase was valued at approximately $751,605, with an average price of $7.28 per share. This move comes after Benzeno sold 11,034 shares just a few days earlier on June 26 for $231,714.
Earlier Insider Transactions
In addition to Benzeno's recent purchase, other insiders have been active recently. For instance, on June 25, Susan Bobulsky, the Chief Commercial Officer for Minimal Residual Disease (MRD), sold 5,000 shares for about $102,500. Michelle Renee Griffin also sold 52,084 shares on the same day, valued at $1,051,055. Harlan Robins, the Chief Scientific Officer, sold 6,160 shares on June 16 for around $110,942. This pattern of selling by other executives contrasts with Benzeno's recent purchase, suggesting a possible strategic move to strengthen her position in the company.
Stock Performance and Market Context
As of June 29, 2026, Adaptive Biotechnologies was trading at $22.16, which is still below its 52-week high of $28.78 and significantly above its low of $12.00. The stock is navigating a complex market environment, reflecting the company's growth potential but also its challenges as it reports losses. With Benzeno's investment, it may signal her confidence in the company's direction amidst this fluctuating performance.
Analysts Set New Price Targets
Analysts have a generally positive outlook on Adaptive Biotechnologies. On October 13, 2026, TD Cowen maintained a Buy rating with a price target of $32.00, up from $28.00. Morgan Stanley also maintained an Equal-Weight rating with a revised target of $27.00. Overall, the average target price across several firms is about $26.36, indicating strong support for the stock's potential growth.
What Adaptive Biotechnologies Corporation Does
Adaptive Biotechnologies develops advanced diagnostic tools for immune-related diseases, focusing on the adaptive immune system to provide insights into cancer treatment. Its clonoSEQ test is crucial for monitoring cancer cell levels in patients. This new purchase by Benzeno could reflect a positive belief in the company's innovative offerings and future financial health.
What's Next for Adaptive Biotechnologies Corporation
Looking ahead, the company is set to report its next earnings on November 4, 2026. This upcoming report will be important to see if the company can improve its financial status despite current losses. Investors will also be watching for any new filings or additional insider transactions, as these can signal changes in leadership confidence and company strategy.
Related Filing Alerts
Source: Sharon Benzeno's Form 4 filing on $ADPT (Jun 29, 2026). Find the original filing: ADPT Form 4 filings on SEC EDGAR. Written by software, not financial advice. How we make alerts